BDSI remains committed to the chronic pain community during the COVID-19 pandemic. For more
information on access to our products, please call our customer service line at 1-800-469-0261.
More information is coming soon.
Recent BDSI News
BioDelivery Sciences Announces Five Scientific Poster Presentations at PAINWeek® 2020 National Conference on Pain Management
September 11, 2020
New Scientific Information Further Highlights Differentiated Clinical Profile of BELBUCA® (buprenorphine buccal film) RALEIGH, N.C. , Sept. 11, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International , Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients ...
BioDelivery Sciences to Present at Two Upcoming Investor Conferences
September 3, 2020
RALEIGH, N.C. , Sept. 03, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International , Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that Jeffrey Bailey , Interim Chief Executive ...
BioDelivery Sciences Reports Strong Q2 2020 Results
August 5, 2020
Second Quarter Total Company Net Revenue Increased 23% versus Prior Year to $36.6 Million Second Quarter BELBUCA® Net Sales Increased 34% versus Prior Year to $32.3 Million BELBUCA and Symproic® Each Reach All Time High TRx Volume and Market Share Conference Call and Webcast Scheduled for 8:30 AM ...